Loading
Adagrasib, the second KRAS G12C pill, shrank tumours in about a third of patients with pancreatic cancer and in two in five with bile duct cancer in this basket study, with disease control for several months.
Phase 2 cohort of the KRYSTAL-1 trial in 64 patients with previously treated KRAS G12C-mutated solid tumours other than lung or colorectal cancer, treated with adagrasib 600 mg twice daily. The pancreatic cohort had 21 patients and the biliary tract cohort 12; other tumours included appendiceal, ovarian, endometrial and small bowel cancers.
In pancreatic cancer the objective response rate was about 33 percent, with median progression-free survival of 5.4 months and median overall survival of 8.0 months; in biliary tract cancer the response rate was about 42 percent. Treatment-related adverse events were mostly gastrointestinal and manageable with dose reduction.
Adagrasib joins sotorasib as a later-line option for KRAS G12C pancreatic cancer in guidelines; both drugs are the template for the G12D and pan-RAS inhibitors now in pancreatic trials.
Shares KRAS G12C, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Adagrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares KRAS G12C, Adagrasib, KRAS & RAS inhibitors, KRAS.
Shares Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C, Adagrasib, KRAS & RAS inhibitors, KRAS.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, KRAS.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/